NFKB1 and neoplasm: Thus, although the activity of bivalent IAP antagonists toward inhibiting p65/NF-κB may vary depending on cell type in vivo, IAP antagonists might offer therapeutic opportunities for diseases associated with inflammation and immune regulation in addition to their anti-tumor properties.